Imara Begins Phase 2 Sickle Cell Disease Trial Testing IMR-687 in Adults
Imara, a pharmaceutical company developing new therapies for sickle cell disease (SCD), has successfully dosed the first patient enrolled in its clinical trial evaluating escalating doses of IMR-687 in adult patients with SCD. The Phase 2 trial (NCT03401112) is currently recruiting participants and expects to enroll…